Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.

abstract：INTRODUCTION:Gout is a common disease responsible for recurrent flares triggered by the deposition of monosodium urate crystals secondary to longstanding hyperuricaemia. The management of gout implies both the treatment of flares and the treatment of hyperuricaemia itself. Recent improvement in the understanding of the...

journal_title：Expert opinion on pharmacotherapy

authors： Pascart T,Richette P

更新日期：2017-08-01 00:00:00

abstract：INTRODUCTION:Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade,...

journal_title：Expert opinion on pharmacotherapy

authors： Samples LS,Graf SA

更新日期：2018-10-01 00:00:00

abstract：INTRODUCTION:Radioiodine [RAI]-resistant advanced and progressive differentiated thyroid cancer [DTC], although rare, constitutes a real challenge as its prognosis is poor and available therapeutic options, until now, have been limited. Discovery of a crucial role of distinct tyrosine kinases in DTC pathogenesis opened...

journal_title：Expert opinion on pharmacotherapy

authors： Krajewska J,Kukulska A,Jarzab B

更新日期：2016-08-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. AREAS COVERED IN THIS REVIEW:Thi...

journal_title：Expert opinion on pharmacotherapy

authors： Spina M,Gloghini A,Tirelli U,Carbone A

更新日期：2010-10-01 00:00:00

abstract：INTRODUCTION:Moderate-to-severe AD burdens a large proportion of AD patients and may represent an inadequacy of treatment options available for resistant disease. AREAS COVERED:This review provides an overview of the therapies for moderate-to-severe AD in late-stage development and in the clinic, and focuses on barici...

journal_title：Expert opinion on pharmacotherapy

authors： Mendes JT,Balogh EA,Strowd LC,Feldman SR

更新日期：2020-06-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Inhibition of the aromatase enzyme in postmenopausal women reduces levels of estrogens, which is of therapeutic value in hormone-sensitive breast cancer. Exemestane is a third-generation steroidal irreversible inactivator of the aromatase enzyme used in early and advanced breast cancer for the t...

journal_title：Expert opinion on pharmacotherapy

authors： Bertelli G,Gangadhara S

更新日期：2010-08-01 00:00:00

abstract：INTRODUCTION:Since the recognition of inherited sodium (Na(+)) channel disease, the cardiac Na(+) channel has been extensively studied. Both loss-of-function and gain-of-function mutations of the cardiac Na(+) channel are associated with cardiac arrhythmia and sudden cardiac death. Pathophysiological mechanisms that ma...

journal_title：Expert opinion on pharmacotherapy

authors： van Hoeijen DA,Blom MT,Tan HL

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Sitagliptin is a highly selective oral dipeptidyl peptidase-4 inhibitor. This drug increases the plasma concentration of active glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide. These two hormones then simulate the secretion of insulin in a glucose-dependent manner and inhibit glu...

journal_title：Expert opinion on pharmacotherapy

authors： Gagliardino JJ,Santoro S,Arellano S,Di Girolamo G

更新日期：2008-06-01 00:00:00

abstract：INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: I...

journal_title：Expert opinion on pharmacotherapy

authors： Raoul JL,Gilabert M,Adhoute X,Edeline J

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias. The Cardiac Arrhythmia Suppression Trial (CAST), conducted to test...

journal_title：Expert opinion on pharmacotherapy

authors： Apostolakis S,Oeff M,Tebbe U,Fabritz L,Breithardt G,Kirchhof P

更新日期：2013-02-01 00:00:00

abstract：INTRODUCTION:Psoriasis is a chronic, inflammatory disease afflicting 2% of the US population; it results in significant morbidity. The annual healthcare costs related to psoriasis are an estimated $11.3 billion and, with an expanding biologic market, an updated costs analysis is needed. AREAS COVERED:Current treatment...

journal_title：Expert opinion on pharmacotherapy

authors： Staidle JP,Dabade TS,Feldman SR

更新日期：2011-09-01 00:00:00

abstract：:Urinary tract infections (UTIs) are among the most commonly encountered bacterial infections. Acute uncomplicated UTIs in adults include episodes of cystitis and pyelonephritis. The main uropathogens causing uncomplicated UTIs have, in the past, been fairly predictable and they have generally been susceptible to sever...

journal_title：Expert opinion on pharmacotherapy

authors： Garrison J,Hooton TM

更新日期：2001-08-01 00:00:00

abstract：INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

journal_title：Expert opinion on pharmacotherapy

authors： Spasovski G

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Following more than 20 years of Interferon (IFN)-based treatment for hepatitis C virus (HCV), the understanding of viral life cycle led to the development of new antiviral drugs directly targeting HCV replication steps. Daclatasvir (DCV) is a potent inhibitor of non-structural NS5A HCV protein with pangeno...

journal_title：Expert opinion on pharmacotherapy

authors： Degasperi E,Aghemo A,Colombo M

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Pulmonary alveolar proteinosis (PAP) is a heterogeneous group of rare diseases characterized by the abnormal production and impaired degradation of pulmonary surfactant as a result of malfunctioning of alveolar macrophages. This is due to the downstream dysregulation of the GM-CSF pathway, which can be cau...

journal_title：Expert opinion on pharmacotherapy

authors： Antoniu SA,Rajnoveanu R,Grigore M,Antohe I

更新日期：2020-08-01 00:00:00

abstract：INTRODUCTION:Transurethral resection of bladder tumor (TURBT) is the gold standard initial diagnostic intervention for bladder cancer and provides diagnostic, therapeutic and prognostic benefit in non-muscle-invasive bladder cancer (NMIBC). However, TURBT alone is inadequate for optimal management of NMIBC, as patients...

journal_title：Expert opinion on pharmacotherapy

authors： Patel SG,Cohen A,Weiner AB,Steinberg GD

更新日期：2015-04-01 00:00:00

abstract：INTRODUCTION:Women are more vulnerable to the development of major depressive disorder (MDD) than men. Although several epidemiological studies have investigated the association between antidepressants and the risk of developing cancer, different methodologies were applied and as a result most of the results were incon...

journal_title：Expert opinion on pharmacotherapy

authors： Pae CU

更新日期：2012-02-01 00:00:00

abstract：INTRODUCTION:Hodgkin lymphoma (HL) is a lymphoid malignancy with an incidence of 2 - 3/100,000/year. Young adults are most often affected. Due to the development of highly active multi-agent chemotherapy protocols and the optimization of radiotherapy (RT) fields and doses, HL has become one of the malignancies with the...

journal_title：Expert opinion on pharmacotherapy

authors： Eichenauer DA,Böll B,Diehl V

更新日期：2014-06-01 00:00:00

abstract：:Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial ...

journal_title：Expert opinion on pharmacotherapy

authors： Piérard GE,Arrese JE,Piérard-Franchimont C

更新日期：2000-01-01 00:00:00

abstract：:Colorectal cancer is one of the most common types of cancer in both men and women. Multiple chemotherapy combinations exist; however, there is currently no strategy for individualised therapy selection prior to treatment. Genetic polymorphisms in genes involved in the metabolism, transport or targets for the commonly ...

journal_title：Expert opinion on pharmacotherapy

authors： Marsh S

更新日期：2005-12-01 00:00:00

abstract：:Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and represents a leading cause of sudden cardiac death as well as a prevalent cause of heart failure and stroke. HCM is characterized by a very complex pathophysiology, consisting of heterogeneous clinical manifestations a...

journal_title：Expert opinion on pharmacotherapy

authors： Spoladore R,Fragasso G,Pannone L,Slavich M,Margonato A

更新日期：2020-02-01 00:00:00

abstract：INTRODUCTION:Chronic obstructive pulmonary disease (COPD) is a complex respiratory disorder, whose medical and socioeconomic burden as one of the main causes of morbidity and mortality is increasing worldwide. COPD pathophysiology includes chronic airway/lung inflammation and progressive airflow limitation. Therefore, ...

journal_title：Expert opinion on pharmacotherapy

authors： Pelaia G,Muzzio CC,Vatrella A,Maselli R,Magnoni MS,Rizzi A

更新日期：2015-01-01 00:00:00

abstract：:Candesartan is a long-acting angiotensin receptor antagonist that is well absorbed from the gastrointestinal tract, with insurmountable receptor binding abilities. Recent studies have shown candesartan to be an effective therapy for heart failure patients, producing a significant reduction in mortality and morbidity. ...

journal_title：Expert opinion on pharmacotherapy

authors： McKelvie RS

更新日期：2006-10-01 00:00:00

abstract：INTRODUCTION:Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK),...

journal_title：Expert opinion on pharmacotherapy

authors： Yamaoka K,Tanaka Y

更新日期：2014-01-01 00:00:00

abstract：:Alprazolam-XR is an extended-release formulation of alprazolam designed to deliver sustained therapeutic concentrations for 24 h after once-daily dosing. Plasma concentrations gradually decline as the time for the next dose approaches, but still remain above therapeutic minimum levels. The anti-panic efficacy of alpra...

journal_title：Expert opinion on pharmacotherapy

authors： Rickels K

更新日期：2004-07-01 00:00:00

abstract：INTRODUCTION:The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people worldwide and has contributed to over 650,000 deaths. This review synthesizes the literature on COVID-19 pharmacotherapy to inform practice and policymaking. A...

journal_title：Expert opinion on pharmacotherapy

authors： Khan S,Gionfriddo MR,Cortes-Penfield N,Thunga G,Rashid M

更新日期：2020-10-01 00:00:00

abstract：INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

journal_title：Expert opinion on pharmacotherapy

authors： Daniels LM,Kufel WD

更新日期：2018-11-01 00:00:00

abstract：INTRODUCTION:Aripiprazole long acting once-monthly (AOM) is approved for the treatment of schizophrenia in adults. Despite recent evidence of AOM efficacy in the acute treatment of schizophrenia, it is recommended that AOM should be started once the acute symptoms are controlled and patients are stabilized. However, th...

journal_title：Expert opinion on pharmacotherapy

authors： Amodeo G,Candiracci C,Capecci I,De Filippis S,Giuliani S,Guerani G,Tomasetti C,Villari V,Fagiolini A

更新日期：2016-11-01 00:00:00

abstract：INTRODUCTION:During the past decade, there have been significant advances in the pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently available treatment options, anti-vascular endothelial growth factors (anti-VEGF) agents are the most favored agents due to their efficacy and safety....

journal_title：Expert opinion on pharmacotherapy

authors： Agarwal A,Parriott J,Demirel S,Argo C,Sepah YJ,Do DV,Nguyen QD

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Venous thromboembolism (VTE) causes substantial morbidity and mortality worldwide. The traditional treatment of VTE, with an initial therapy with (low molecular weight) heparin or fondaparinux and a continued treatment with vitamin K antagonists, is effective but has limitations. AREAS COVERED:The current...

journal_title：Expert opinion on pharmacotherapy

authors： Vanassche T,Vandenbriele C,Peerlinck K,Verhamme P

更新日期：2015-04-01 00:00:00